A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a ...

Bionova Scientific announced Thursday it would bring 200 new jobs to The Woodlands over the next several years, bolstering the community's biotech sector.

For kids with the condition, day-to-day activities like going to school or playing with friends can lead to life-threatening ...

The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

The Cambridge research institute launched nearly two years ago with $500 million to support scientific research and development. Approximately 50 staff members will be laid off.

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...